bysans
9/14/2019 - 8:18 AM

kykw

letter,frequency
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
RECURRENT DISEASE,10
CONTROLLED CLINICAL TRIAL,10
BRAIN,10
ANOREXIA,10
DIAGNOSTIC ACCURACY,10
PROTEIN PHOSPHORYLATION,10
SURGICAL TECHNIQUE,10
POSTOPERATIVE PERIOD,10
CANCER GRADING,10
ABDOMINAL PAIN,10
CANCER RADIOTHERAPY,10
CANCER COMBINATION CHEMOTHERAPY,10
DIABETES MELLITUS,10
PROTEIN PROTEIN INTERACTION,10
GENE SEQUENCE,10
ADVERSE EFFECTS,10
GRAPHENE,10
PARTICLE SIZE,10
SCORING SYSTEM,10
ANALOGS AND DERIVATIVES,10
PREDICTIVE VALUE,10
GENE MUTATION,10
DIZZINESS,10
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
WESTERN BLOTTING,11
ISOLATION AND PURIFICATION,11
CANCER GROWTH,11
CANCER RECURRENCE,11
GLUCOSE,11
HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY,11
ALANINE AMINOTRANSFERASE,11
OBESITY,11
TUMOR VOLUME,11
TEMPERATURE,11
PROTEIN FUNCTION,11
CONSTIPATION,11
NEOPLASM RECURRENCE, LOCAL,11
MUTATION,11
MOLECULAR SEQUENCE DATA,11
VOMITING,11
CELL SURVIVAL,11
MESSENGER RNA,11
SILICA,11
DOSE-RESPONSE RELATIONSHIP, DRUG,11
REPRODUCIBILITY OF RESULTS,11
PNEUMONIA,11
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
SIDE EFFECT,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
APOPTOSIS,12
DNA,12
CANCER PROGNOSIS,12
GENOTYPE,12
KAPLAN-MEIER ESTIMATE,12
TIME FACTOR,12
CARCINOMA, HEPATOCELLULAR,12
BREAST CANCER,12
MULTIPLE CYCLE TREATMENT,12
DOSE RESPONSE,12
DEPRESSION,12
DRUG EFFECTS,12
ACCURACY,12
MAGNETIC RESONANCE IMAGING,12
SIDE EFFECT,12
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
ANEMIA,13
RECEIVER OPERATING CHARACTERISTIC,13
DOWN REGULATION,13
IN VIVO STUDY,13
DIARRHEA,13
IN VITRO STUDY,13
IMAGE ANALYSIS,13
HYPERTENSION,13
ASIAN CONTINENTAL ANCESTRY GROUP,13
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
CELL DIFFERENTIATION,14
LIVER CELL CARCINOMA,14
NAUSEA,14
CASE REPORT,14
REVIEW,14
CYTOLOGY,14
ENZYME ACTIVITY,14
KAPLAN MEIER METHOD,14
PROGRESSION FREE SURVIVAL,14
AGE,14
DIAGNOSTIC TEST ACCURACY STUDY,14
RAT,14
TRANSMISSION ELECTRON MICROSCOPY,14
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
REGRESSION ANALYSIS,15
NEOPLASM STAGING,15
IMMUNOHISTOCHEMISTRY,15
SCHOOL CHILD,15
ECHOGRAPHY,15
CANCER STAGING,15
CELL LINE,15
METHODOLOGY,15
LIVER NEOPLASMS,15
ANTINEOPLASTIC AGENTS,15
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
COMPLICATION,16
DRUG EFFECT,16
TREATMENT DURATION,16
SEX DIFFERENCE,16
DISEASE FREE SURVIVAL,16
CELL CULTURE,16
PATHOPHYSIOLOGY,16
PHENOTYPE,16
NANOPARTICLES,16
CROSS-SECTIONAL STUDY,17
DISEASE-FREE SURVIVAL,17
PRESCHOOL CHILD,17
CELL LINE, TUMOR,17
CELL LINE, TUMOR,17
CROSS-SECTIONAL STUDY,17
DISEASE-FREE SURVIVAL,17
PRESCHOOL CHILD,17
DISEASE-FREE SURVIVAL,17
PRESCHOOL CHILD,17
CELL LINE, TUMOR,17
CROSS-SECTIONAL STUDY,17
CROSS-SECTIONAL STUDY,17
DISEASE-FREE SURVIVAL,17
PRESCHOOL CHILD,17
CELL LINE, TUMOR,17
NUCLEOTIDE SEQUENCE,18
CLINICAL FEATURE,18
SENSITIVITY AND SPECIFICITY,18
KOREAN (PEOPLE),18
SENSITIVITY AND SPECIFICITY,18
KOREAN (PEOPLE),18
NUCLEOTIDE SEQUENCE,18
CLINICAL FEATURE,18
CLINICAL FEATURE,18
SENSITIVITY AND SPECIFICITY,18
KOREAN (PEOPLE),18
NUCLEOTIDE SEQUENCE,18
CLINICAL FEATURE,18
SENSITIVITY AND SPECIFICITY,18
KOREAN (PEOPLE),18
NUCLEOTIDE SEQUENCE,18
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
CANCER SURGERY,19
INFANT,19
MULTIVARIATE ANALYSIS,19
CELL PROLIFERATION,19
HEALTH SURVEY,19
DISEASE SEVERITY,19
CROSS-SECTIONAL STUDIES,19
QUALITY OF LIFE,19
COHORT STUDIES,19
QUESTIONNAIRE,20
INTERMETHOD COMPARISON,20
DIAGNOSTIC IMAGING,20
GENE EXPRESSION,20
DIAGNOSTIC IMAGING,20
GENE EXPRESSION,20
QUESTIONNAIRE,20
INTERMETHOD COMPARISON,20
QUESTIONNAIRE,20
INTERMETHOD COMPARISON,20
DIAGNOSTIC IMAGING,20
GENE EXPRESSION,20
DIAGNOSTIC IMAGING,20
GENE EXPRESSION,20
QUESTIONNAIRE,20
INTERMETHOD COMPARISON,20
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
CANCER PATIENT,21
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
CANCER PATIENT,21
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
CANCER PATIENT,21
CANCER PATIENT,21
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
CANCER PATIENT,21
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
CANCER PATIENT,21
BLOOD,21
CANCER SURVIVAL,21
CHILD, PRESCHOOL,21
HISTOPATHOLOGY,21
DISEASE COURSE,21
ANIMAL,22
TREATMENT RESPONSE,22
ANTINEOPLASTIC AGENT,22
SIGNAL TRANSDUCTION,22
ANTINEOPLASTIC AGENT,22
SIGNAL TRANSDUCTION,22
ANIMAL,22
TREATMENT RESPONSE,22
ANTINEOPLASTIC AGENT,22
SIGNAL TRANSDUCTION,22
ANIMAL,22
TREATMENT RESPONSE,22
ANTINEOPLASTIC AGENT,22
SIGNAL TRANSDUCTION,22
ANIMAL,22
TREATMENT RESPONSE,22
PHYSIOLOGY,23
DRUG SAFETY,23
PHYSIOLOGY,23
DRUG SAFETY,23
INCIDENCE,24
OVERALL SURVIVAL,24
INCIDENCE,24
OVERALL SURVIVAL,24
COMPUTER ASSISTED TOMOGRAPHY,25
DISEASE ASSOCIATION,25
ANIMAL TISSUE,25
VERY ELDERLY,25
PREVALENCE,25
DISEASE ASSOCIATION,25
ANIMAL TISSUE,25
VERY ELDERLY,25
PREVALENCE,25
COMPUTER ASSISTED TOMOGRAPHY,25
COMPUTER ASSISTED TOMOGRAPHY,25
DISEASE ASSOCIATION,25
ANIMAL TISSUE,25
VERY ELDERLY,25
PREVALENCE,25
DISEASE ASSOCIATION,25
ANIMAL TISSUE,25
VERY ELDERLY,25
PREVALENCE,25
COMPUTER ASSISTED TOMOGRAPHY,25
DISEASE ASSOCIATION,25
ANIMAL TISSUE,25
VERY ELDERLY,25
PREVALENCE,25
COMPUTER ASSISTED TOMOGRAPHY,25
RISK ASSESSMENT,26
TIME FACTORS,26
NUCLEAR MAGNETIC RESONANCE IMAGING,26
NUCLEAR MAGNETIC RESONANCE IMAGING,26
RISK ASSESSMENT,26
TIME FACTORS,26
RISK ASSESSMENT,26
TIME FACTORS,26
NUCLEAR MAGNETIC RESONANCE IMAGING,26
FOLLOW-UP STUDIES,27
ANIMAL MODEL,27
BODY MASS,27
ANIMAL MODEL,27
BODY MASS,27
FOLLOW-UP STUDIES,27
FOLLOW-UP STUDIES,27
ANIMAL MODEL,27
BODY MASS,27
RANDOMIZED CONTROLLED TRIAL,28
DRUG EFFICACY,30
PROSPECTIVE STUDIES,30
CHEMISTRY,30
DRUG EFFICACY,30
PROSPECTIVE STUDIES,30
CHEMISTRY,30
CHEMISTRY,30
DRUG EFFICACY,30
PROSPECTIVE STUDIES,30
MORTALITY,31
COHORT ANALYSIS,31
MORTALITY,31
COHORT ANALYSIS,31
METABOLISM,32
OUTCOME ASSESSMENT,32
SURVIVAL RATE,32
ANIMAL CELL,32
OUTCOME ASSESSMENT,32
SURVIVAL RATE,32
ANIMAL CELL,32
METABOLISM,32
OUTCOME ASSESSMENT,32
SURVIVAL RATE,32
ANIMAL CELL,32
METABOLISM,32
SURVIVAL RATE,32
ANIMAL CELL,32
METABOLISM,32
OUTCOME ASSESSMENT,32
HUMAN TISSUE,33
PROGNOSIS,33
HUMAN TISSUE,33
PROGNOSIS,33
GENETICS,34
CHILD,36
COMPARATIVE STUDY,38
HUMAN CELL,38
COMPARATIVE STUDY,38
HUMAN CELL,38
PROSPECTIVE STUDY,39
PROTEIN EXPRESSION,39
PROCEDURES,39
PROTEIN EXPRESSION,39
PROCEDURES,39
PROSPECTIVE STUDY,39
PROSPECTIVE STUDY,39
PROTEIN EXPRESSION,39
PROCEDURES,39
ANIMAL EXPERIMENT,40
AGED, 80 AND OVER,40
MICE,40
ANIMAL EXPERIMENT,40
AGED, 80 AND OVER,40
MICE,40
ANIMAL EXPERIMENT,40
AGED, 80 AND OVER,40
MICE,40
CLINICAL TRIAL,42
MOUSE,43
RISK FACTORS,43
MOUSE,43
RISK FACTORS,43
ADOLESCENT,44
RISK FACTOR,48
PATHOLOGY,48
RISK FACTOR,48
PATHOLOGY,48
YOUNG ADULT,53
RETROSPECTIVE STUDIES,55
MULTICENTER STUDY,55
RETROSPECTIVE STUDIES,55
MULTICENTER STUDY,55
CLINICAL ARTICLE,57
ANIMALS,60
UNCLASSIFIED DRUG,60
ANIMALS,60
UNCLASSIFIED DRUG,60
TREATMENT OUTCOME,62
FOLLOW UP,63
RETROSPECTIVE STUDY,64
KOREA,68
NONHUMAN,76
REPUBLIC OF KOREA,85
SOUTH KOREA,86